Supplementary material

_____

Burden of Recurrent Hospitalizations Following an Admission for Acute Heart Failure: Preserved Versus Reduced Ejection Fraction

_____

Table 1 of the supplementary material

Crude Incidence Rates of Specific Causes of CV Death in HFpEF Vs HFrEF

	Rates (per 100 person-years)		*P*-value
	HFpEF	**HFrEF**	
AMI-related death	0.3	0.5	.134
Stroke-related death	0.4	0.5	.452
HF-related death	4.3	5.7	.015
Sudden cardiac death	0.9	1.5	.098
Other CV deaths	0.7	0.7	.854

AMI, acute myocardial infarction; CV, cardiovascular; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; HFrEF, heart failure with reduced ejection fraction.

Table 2 of the supplementary material

All the Covariates and Their Estimates in the Final Multivariate Model for All-cause Repeat Hospitalizations

	IRR	95%CI	*P*-value
Age (per 10-y increase)	1.14	1.08-1.20	<.001
Male sex	0.99	0.87-1.11	.817
NYHA class III/IV	1.16	1.02-1.32	.024
First HF admission	0.47	0.42-0.52	<.001
Hypertension	1.14	1.00-1.30	.049
Diabetes	1.19	1.07-1.32	.001
Former tobacco use	1.34	1.14-1.49	<.001
Peripheral artery disease	1.17	0-98-1.40	.079
Dementia	1.49	0.99-2.27	.058
COPD	1.29	1.13-1.46	<.001
Previous stroke	1.16	0.99-1.37	.072
ICD carrier	1.64	1.20-2.26	.002
Previous MI	1.28	0.98-1.68	<.001
Interaction atrial fibrillation*type of rhythm			<.001*
Heart rate in sinus rhythm, per increase in 10 bpm	1.02	0.99-1-05	.170
Heart rate in atrial fibrillation, per increase in 10 bpm	0.96	0.94-0.98	.002
Atrial fibrillation*Heart rate	0.99	0.99-1.00	.002
Urea (per 10 mg/dL increase)	1.04	1.02-1.06	<.001
Hemoglobin (per 1.0 gr/dL increase)	0.91	0.88-0.93	<.001
Sodium (per 1.0 mEq/L increase)	0.99	0.98-0.99	.034
NT-proBNP (per 1000 pg/mL increase)	1.02	1.01-1.03	<.001
Beta-blockers	0.77	0.69-0.85	<.001
HFpEF	1.04	0.93-1.17	.461

95%CI, 95% confidence interval; COPD, chronic obstructive pulmonary disease; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; ICD, Implantable cardioverter defibrillator; IRR, incident rate ratios; NYHA, New York Heart Association; NT-proBNP, N-terminal pro-B-type natriuretic peptide; MI, myocardial infarction.

P-value for interaction.

Table 3 of the supplementary material

All the Covariates and Their Estimates in the Final Multivariate Model for CV Repeat Hospitalizations

	IRR	95%CI	*P*-value
Age (per 10-y increase)	1.16	1.10-1.23	<.001
Male sex	0.94	0.82-1.08	.397
First HF admission	0.27	0.24-0.31	<.001
Diabetes	1.21	1.08-1.36	.001
Former tobacco use	1.25	1.08-1.46	.003
Dementia	1.62	1.01-2.63	.047
Previous stroke	1.19	0.99-1.44	.069
ICD carrier	1.54	1.08-2.21	.017
Previous MI	1.34	1.18-1.53	<.001
Interaction atrial fibrillation*type of rhythm			.008*
Heart rate in sinus rhythm, per increase in 10 bpm	1.01	0.90-0.98	.452
Heart rate in atrial fibrillation, per increase in 10 bpm	0.96	0.93-0.98	.002
Urea (per 10 mg/dL increase)	1.03	1.01-1.05	.025
Hemoglobin (per 1.0 gr/dL increase)	0.92	0.89-0.96	<.001
Sodium (per 1.0 mEq/L increase)	0.98	0.97-0.99	.016
NT-proBNP (per 1000 pg/mL increase)	1.03	1.02-1.04	<0.001
Beta-blockers	0.85	0.76-0.96	0.007
HFpEF	0.93	0.82-1.06	0.304

95%CI, 95% confidence interval; HF, heart failure; HFpEF, heart failure with preserved ejection fraction; ICD, Implantable cardioverter defibrillator; IRR, incident rate ratios; NYHA, New York Heart Association; NT-proBNP, N-terminal pro-B-type natriuretic peptide; MI, myocardial infarction.

P-value for interaction

Table 4 of the supplementary material

All the Covariates and Their Estimates in the Final Multivariate Model for non-CV Repeat Hospitalizations

	IRR	95%CI	*P*-value
Age (per 10-y increase)	1.12	1.04-1.21	.004
Male sex	1.05	0.88-1.27	.545
NYHA class III/IV	1.36	1.11-1.66	.003
Diabetes	1.27	1.08-1.48	.003
Former tobacco use	1.34	1.14-1.49	<.001
Peripheral artery disease	1.20	0.91-1.58	.199
Malign neoplasia	1.24	1.05-1.47	.010
COPD	1.69	1.40-2.01	<.001
Previous stroke	1.17	0.90-1.51	.231
ICD carrier	1.92	1.16-3.19	.011
Previous MI	1.09	0.90-1.31	.384
Interaction atrial fibrillation*type of rhythm			.063*
Heart rate in sinus rhythm, per increase in 10 bpm	1.03	0.98-1.08	.241
Heart rate in atrial fibrillation, per increase in 10 bpm	0.97	0.94-1.01	.182
Urea (per 100 mg/dL increase)	1.05	1.02-1.08	.001
Hemoglobin (per 1.0 g/dL increase)	0.89	0.85-0.93	<.001
Beta-blockers	0.71	0.60-0.83	<.001
HFpEF	1.24	1.05-1.47	.012

95%CI, 95% confidence interval; COPD, chronic obstructive pulmonary disease; HFpEF, heart failure with preserved ejection fraction; ICD, Implantable cardioverter defibrillator; IRR, incident rate ratios; NYHA, New York Heart Association; MI, myocardial infarction.

P-value for interaction

Table 5 of the supplementary material

All the Covariates and Their Estimates in the Final Multivariate Model for HF-related Repeat Hospitalizations

	IRR	95%CI	P-value
Age (per 10-y increase)	1.02	1.01-1-03	<.001
Male sex	1.02	0.88-1.18	.749
NYHA class III/IV	1.11	0.94-1.31	.208
First HF admission	0.22	0.19-0.26	<.001
Diabetes	1.14	1.00-1.31	.044
Dementia	1.67	0.98-2.83	.057
COPD	1.18	1.00-1.39	.040
ICD carrier	1.55	1.04-2.31	.031
Previous MI	1.29	1.11-1.50	.001
SBP	0.99	0.99-1.00	.289
Atrial fibrillation	2.23	1.35-3.69	.002
Interaction atrial fibrillation*type of rhythm			.013*
Heart rate in sinus rythm, per increase in 10 bpm	1.02	0.98-1.06	.300
Heart rate in atrial fibrillation, per increase in 10 bpm	0.96	0.93-0.99	.010
Urea (per 10 mg/dL increase)	1.03	1.01-1.05	.029
Hemoglobin (per 1.0 gr/dL increase)	0.92	0.89-0.96	<.001
Sodium (per 1 mEq/L increase)	0.98	0.97-0.99	.010
NT-prpBNP (per 1000 pg/mL increase)	1.03	1.02-1.04	<.001
Beta-blockers	0.79	0.69-0.90	.001
ACEI inhibitors or ARB	0.88	0.77-1.02	.091
HFpEF	0.96	0.83-1.13	.677

ACEI inhibitors, angiotensin converting-enzyme inhibitors; ARB, angiotensin receptor blockers; CI, Confidence interval;

COPD, chronic obstructive pulmonary disease; HF, heart failure; HFpEF, heart failure with preserved ejection fraction;

ICD, Implantable cardioverter defibrillator; IRR, incident rate ratios; NYHA, New York Heart Association; NT-proBNP,

N-terminal pro-B-type natriuretic peptide; MI, myocardial infarction; SBP, systolic blood pressure.

*P-value for interaction